WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407229
Description: BFH772, a structure analogue of BAW2881, is a potent and selective VEGF inhibitor. BFH772 is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. BFH772 inhibits the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases, with IC50 values ranging between 30 and 160 nM.
MedKoo Cat#: 407229
Chemical Formula: C23H16F3N3O3
Exact Mass: 439.1144
Molecular Weight: 439.39
Elemental Analysis: 62.87; H, 3.67; F, 12.97; N, 9.56; O, 10.92
Synonym: BFH-772; BFH 772; BFH772.
IUPAC/Chemical Name: 6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide
InChi Key: JNLSTLQFDDAULK-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)
SMILES Code: O=C(C1=C2C=CC(OC3=NC=NC(CO)=C3)=CC2=CC=C1)NC4=CC=CC(C(F)(F)F)=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 439.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
Guido Bold, Christian Schnell, Pascal Furet, Paul McSheehy, Josef Brüggen, Jürgen Mestan, Paul W. Manley, Peter Drückes, Marion Burglin, Ursula Dürler, Jacqueline Loretan, Robert Reuter, Markus Wartmann, Andreas Theuer, Beatrice Bauer-Probst, Georg Martiny-Baron, Peter Allegrini, Arnaud Goepfert, Jeanette Wood, and Amanda Littlewood-Evans
Publication Date (Web): December 2, 2015 (Article)